SARS-CoV-2 neutralizing antibodies (NAb)
Virus-like particles (VLP) Platforms for immunogens, vaccines and drug carriers
Antibody-drug Conjugate (ADC): Pre-made ADC benchmark, MOA, Production and QC
Neutralizing antibodies of virus (SARS2, HIV, HBV, Rabies, RSV, Ebola, Influenza)
Immunoglobulin Fc receptors for Fc&Fc Receptor binding assay
ILIBRA-HuEasy Monoclonal antibody (mab) humanization service (fully humanized ab)
Single domain antibody (Nanobody)
SOCAIL MEDIA
SARS-CoV-2 neutralizing antibodies (NAb)
SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has been spreading rampantly. The global scientific community has responded rapidly to understand immune correlates of protection to develop vaccines and immunotherapeutic against the virus. The RBD of spike plays a critical role in the very first step of the virus life cycle. The neutralizing antibodies (nAbs) that target the receptor binding domain (RBD) of viral spike (S) glycoprotein3.
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
|---|---|---|---|---|---|---|
Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody |
Bamlanivimab |
NA |
SARS-CoV-2 Spike |
Whole mAb |
||
Pre-Made Casirivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Casirivimab |
NA |
SARS-CoV-2Spike RBD |
Whole mAb |
||
Pre-Made Cilgavimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Cilgavimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Etesevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Etesevimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Imdevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Imdevimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Sotrovimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Tixagevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Tixagevimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Adintrevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody |
Adintrevimab |
NA |
SARS-CoV-2 Spike |
Whole mAb |
||
Pre-Made Amubarvimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Amubarvimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Beludavimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Beludavimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Enuzovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Enuzovimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Lomtegovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Lomtegovimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Rimteravimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Rimteravimab |
NA |
SARS-CoV-2 Spike RBD |
Mixed Nanobody (VHH-CH2-CH3 dimer) |
||
Pre-Made Romlusevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Romlusevimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Upanovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
Upanovimab |
NA |
SARS-CoV-2 Spike RBD |
Whole mAb |
||
Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe?acute?respiratory syndrome?coronavirus?2 RBD |
ensovibep |
NA |
Severe?acute?respiratory syndrome?coronavirus?2 RBD |
Recombinant Protein |
Reference:
1. Niu, L., et al., A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Front Immunol, 2021. 12: p. 647934.
